Profile data is unavailable for this security.
About the company
Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.
- Revenue in PLN (TTM)373.90m
- Net income in PLN-2.89m
- Incorporated2019
- Employees434.00
- LocationSelvita SAHexagon, Ul. Podole 79KRAKOW 30-394PolandPOL
- Phone+48 123005001
- Fax+48 122974701
- Websitehttps://selvita.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innate Pharma SA | 25.34m | -194.48m | 579.58m | 181.00 | -- | 26.23 | -- | 22.87 | -0.5497 | -0.5497 | 0.0714 | 0.0558 | 0.0491 | -- | 15.81 | 33,149.17 | -37.68 | -13.19 | -52.10 | -17.17 | 49.52 | 91.15 | -767.52 | -88.46 | -- | -- | 0.8401 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Solar Foods Oyj | 80.70k | -45.04m | 593.15m | 57.00 | -- | 6.61 | -- | 7,349.74 | -0.433 | -0.433 | 0.0008 | 0.7115 | 0.0004 | -- | 0.0037 | 455.00 | -22.45 | -- | -27.05 | -- | 25,931.57 | -- | -55,808.37 | -- | -- | -7.03 | 0.5092 | -- | 275.15 | -- | -22.57 | -- | -- | -- |
| Devyser Diagnostics AB | 99.21m | -3.33m | 594.68m | 116.00 | -- | 4.24 | 83.92 | 5.99 | -0.5142 | -0.5142 | 15.09 | 21.27 | 0.5312 | 1.45 | 4.65 | 2,160,345.00 | -1.95 | -8.59 | -2.30 | -9.76 | 80.61 | 81.08 | -3.67 | -22.20 | 2.36 | 0.6429 | 0.1278 | -- | 15.49 | 30.70 | 86.34 | -- | 83.06 | -- |
| Heidelberg Pharma AG | 12.83m | -110.55m | 594.70m | 114.00 | -- | 13.37 | -- | 46.36 | -0.558 | -0.558 | 0.0647 | 0.2251 | 0.0507 | 0.0329 | 69.14 | 28,928.10 | -43.69 | -40.90 | -50.29 | -58.51 | 84.66 | 55.95 | -861.83 | -228.64 | 3.55 | -- | 0.7766 | -- | -30.53 | -1.29 | 4.74 | -- | -13.09 | -- |
| Xlife Sciences AG | 3.90m | 142.98m | 603.35m | 17.00 | 5.52 | 0.4258 | 3.15 | 154.60 | 4.08 | 4.08 | 0.1284 | 52.84 | 0.0016 | -- | 0.0907 | 49,375.29 | 4.80 | 6.01 | 5.95 | 7.37 | 62.17 | 37.44 | 2,991.34 | 2,987.92 | 1.07 | -- | 0.131 | -- | -15.54 | 10.15 | 130.37 | 100.79 | -13.48 | -- |
| BioInvent International AB | 96.93m | -128.24m | 605.69m | 124.00 | -- | 2.24 | -- | 6.25 | -4.91 | -4.91 | 3.72 | 10.38 | 0.2614 | -- | 4.90 | 2,147,790.00 | -34.58 | -19.38 | -38.20 | -20.57 | -- | -- | -132.30 | -189.97 | 7.31 | -- | 0.0154 | -- | -37.47 | -13.77 | -29.99 | -- | 21.19 | -- |
| Ryvu Therapeutics SA | 69.80m | -118.69m | 609.22m | 294.00 | -- | 8.55 | -- | 8.73 | -5.13 | -5.13 | 3.02 | 3.08 | 0.212 | 12.29 | 7.31 | 237,411.60 | -36.05 | -23.64 | -48.51 | -27.84 | 70.86 | 29.35 | -170.05 | -208.85 | 2.26 | -- | 0.572 | -- | 66.38 | 83.01 | -20.98 | -- | -24.46 | -- |
| Intellego Technologies AB | 292.15m | 75.94m | 614.72m | 64.00 | 7.01 | 11.41 | 7.22 | 2.10 | 6.64 | 6.64 | 23.96 | 4.08 | 2.03 | 11.02 | 15.11 | 11,530,660.00 | 52.66 | -15.74 | 75.55 | -23.48 | 60.32 | 13.73 | 26.00 | -33.49 | 2.53 | 3.94 | 0.0642 | -- | 4.34 | 67.41 | -70,300.74 | -- | 36.08 | -- |
| BioVersys AG | -464.93bn | -464.93bn | 663.42m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.28 | -- | -- | -- |
| Scancell Holdings Plc | 22.71m | -26.57m | 670.36m | 60.00 | -- | -- | -- | 29.52 | -0.0053 | -0.0053 | 0.0047 | -0.0081 | 0.2946 | -- | 8.26 | 78,516.66 | -34.46 | -33.29 | -- | -44.23 | 94.95 | -- | -116.98 | -502.03 | -- | -- | 2.07 | -- | -- | -- | -109.46 | -- | 124.48 | -- |
| Egetis Therapeutics AB (publ) | 24.74m | -135.63m | 718.06m | 40.00 | -- | 5.36 | -- | 29.02 | -0.9237 | -0.9237 | 0.1698 | 0.8571 | 0.0873 | 30.36 | 3.60 | 1,562,500.00 | -47.87 | -39.01 | -69.47 | -46.68 | 19.84 | 61.77 | -548.16 | -577.70 | 1.04 | -35.79 | 0.1951 | -- | 35.36 | 8.94 | 0.3201 | -- | 128.65 | -- |
| Molecular Partners AG | 0.00 | -280.05m | 726.46m | 153.00 | -- | 1.52 | -- | -- | -1.63 | -1.63 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -45.23 | -13.09 | -49.34 | -15.66 | -- | 99.25 | -- | -56.51 | -- | -- | 0.0158 | -- | -29.38 | -24.59 | 12.81 | -- | -17.26 | -- |
| Cereno Scientific AB | 0.00 | -44.85m | 780.27m | 5.00 | -- | 9.63 | -- | -- | -0.3987 | -0.3987 | 0.00 | 0.6572 | 0.00 | -- | -- | -- | -30.72 | -20.10 | -32.58 | -21.72 | -- | -- | -- | -- | -- | -1.94 | 0.4817 | -- | -- | -- | -106.89 | -- | 47.93 | -- |
| Diamyd Medical AB | 137.77k | -72.23m | 787.22m | 41.00 | -- | 8.81 | -- | 5,714.11 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
| Sensorion SA | 0.00 | -118.61m | 789.41m | 68.00 | -- | 1.92 | -- | -- | -0.0931 | -0.0931 | 0.00 | 0.1895 | 0.00 | -- | -- | 0.00 | -32.12 | -34.53 | -38.36 | -43.50 | -- | -- | -- | -- | -- | -- | 0.0265 | -- | -- | -- | -17.72 | -- | 98.90 | -- |
| Selvita SA | 373.90m | -2.89m | 791.12m | 434.00 | -- | 2.50 | 14.98 | 2.12 | -0.1577 | -0.1577 | 20.37 | 17.23 | 0.5983 | 8.96 | 4.97 | 398,187.40 | -0.4629 | 5.76 | -0.5715 | 7.33 | 80.27 | 80.65 | -0.7737 | 8.57 | 0.8823 | 0.7538 | 0.3757 | -- | -1.73 | -- | -108.73 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Selvita SA's reporting currency: Polish New Zloty PLN
38.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Allianz Polska TFI SAas of 30 Jun 2024 | 2.09m | 11.41% |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne SAas of 30 Jun 2024 | 1.90m | 10.36% |
| FORUM TFI SAas of 30 Jun 2024 | 932.71k | 5.08% |
| Allianz Polska PTE SAas of 31 Dec 2024 | 876.22k | 4.77% |
| Vienna PTE SA Vienna Insurance Groupas of 31 Dec 2024 | 350.97k | 1.91% |
| Generali PTE SAas of 31 Dec 2024 | 317.69k | 1.73% |
| Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2025 | 242.14k | 1.32% |
| PKO TFI SAas of 30 Jan 2026 | 147.75k | 0.81% |
| AgioFunds TFI SAas of 28 Jan 2026 | 121.04k | 0.66% |
| Investors TFI SAas of 30 Jun 2025 | 111.91k | 0.61% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
